EX-99.1 2 rxst-ex99_1.htm EX-99.1 EX-99.1

 

img261313502_0.jpg

Exhibit 99.1

 

 

 

RXSIGHT, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

 

Aliso Viejo, Calif. (Nasdaq: RXST) – August 7, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025.

 

Key Company Highlights

•
Reported second quarter 2025 revenue of $33.6 million, representing a decrease of 4% compared to the second quarter of 2024, reflecting:
•
The sale of 27,380 Light Adjustable Lenses (LAL®/LAL+®), representing a 13% increase in procedure volume compared to the second quarter of 2024;
•
The sale of 40 Light Delivery Devices (LDD™s), representing a 49% decrease compared to the second quarter of 2024; and
•
An installed base of 1,084 LDDs as of June 30, 2025, representing a 34% increase from 810 LDDs at the end of the second quarter of 2024;
•
During the second quarter, the company received FDA approval to expand the Light Adjustable Lens dioptric power range to -2.0 to +3.0 diopters, along with approvals for new LDD software updates.
•
In the quarter, the company launched the RxSight® Light Adjustable Lens system in South Korea, with a subsequent launch in Singapore in July.
•
Announced a realignment of its commercial organization.
•
Reaffirmed its 2025 full-year revenue, gross margin and operating expense guidance provided on July 8, 2025.

 

“With nearly 1,100 LDD-enabled practices in place, we see significant opportunity to accelerate growth by deepening engagement with our existing customers while strategically expanding our installed base,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “Our newly launched Customer Success Organization, supported by targeted investments in clinical affairs, marketing, and education, is designed to elevate onboarding, strengthen ongoing practice support and advance the mastery of post-operative vision optimization. Together with our realigned commercial structure and selective investments in high-impact areas, these initiatives position us to fully realize the clinical value of the LAL and drive sustained growth.”

Second Quarter Financial Results

In the second quarter of 2025, total revenue was $33.6 million, representing a decrease of 4% compared to $34.9 million in the second quarter of 2024. During the quarter, LAL revenue increased 13% while LDD revenue decreased 50%, compared to the second quarter of 2024.

 

 

img261313502_0.jpg

Gross profit for the second quarter of 2025 was $25.2 million or 74.9% of revenue, an increase of $0.9 million compared to gross profit of $24.3 million or 69.5% of revenue for the second quarter of 2024. The increase in gross profit was primarily driven by the favorable shift in product mix toward LAL sales.

Total operating expenses for the second quarter of 2025 were $39.2 million, a 20% increase from $32.6 million in the second quarter of 2024, reflecting the company’s ongoing investments to support increased LAL sales volume, and advance its research and development pipeline.

In the second quarter of 2025, the company reported a net loss of $(11.8) million, or $(0.29) per basic and diluted share, compared to a net loss of $(6.1) million, or $(0.16) per basic and diluted share in the second quarter of 2024. Adjusted net loss in the second quarter of 2025 was $(3.2) million, or $(0.08) per basic and diluted share, compared to an adjusted net gain of $26,000, or $0.00 per basic and diluted share in the second quarter of 2024.

Cash, cash equivalents and short-term investments decreased by $1.8 million as of June 30, 2025, to $227.5 million compared to $229.3 million as of March 31, 2025.

 

2025 Guidance

The company reiterated its 2025 full-year revenue, gross margin and operating expense guidance as follows:

•
Revenue of $120.0 million to $130.0 million, representing an implied decrease of 14% to 7% compared to 2024;
•
Gross margin in the range of 72% to 74%, representing an implied increase of 130 basis points to 330 basis points compared to 2024;
•
Operating expenses in the range of $145.0 million to $155.0 million, representing an implied increase of 7% to 14% compared to 2024; and
•
Operating expenses include non-cash stock-based compensation expense in the range of $27.0 million to $30.0 million.

Conference Call

On Thursday, August 7, 2025, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2025 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 9977116. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

 

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

 

 

img261313502_0.jpg

Forward-Looking Statements

This press release contains forward-looking statements, including: statements concerning the Company’s projected revenue, gross margin, operating expense and non-cash stock based compensation in 2025; the Company’s potential for accelerated growth by deepening engagement with its existing customers while strategically expanding its installed base; the benefits expected from the Company’s realigned commercial structure and selective investments in high-impact areas; and the Company’s belief that these initiatives will enable it to fully realize the clinical value of the Light Adjustable Lens and drive sustained growth. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended June 30, 2025, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

 

Company Contact:

Shelley B. Thunen

Chief Financial Officer

sthunen@rxsight.com

 

Investor Relations Contact:

Oliver Moravcevic

VP, Investor Relations

omoravcevic@rxsight.com

 

 

 

img261313502_0.jpg

RxSIGHT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS (UNAUDITED)

(In thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

 

$

33,637

 

 

$

34,887

 

 

$

71,531

 

 

$

64,399

 

Cost of sales

 

 

8,447

 

 

 

10,637

 

 

 

18,013

 

 

 

19,464

 

Gross profit

 

 

25,190

 

 

 

24,250

 

 

 

53,518

 

 

 

44,935

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

28,976

 

 

 

24,292

 

 

 

57,611

 

 

 

47,616

 

Research and development

 

 

10,217

 

 

 

8,291

 

 

 

20,584

 

 

 

16,322

 

Total operating expenses

 

 

39,193

 

 

 

32,583

 

 

 

78,195

 

 

 

63,938

 

Loss from operations

 

 

(14,003

)

 

 

(8,333

)

 

 

(24,677

)

 

 

(19,003

)

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(5

)

 

 

(6

)

 

 

(11

)

 

 

(11

)

Interest and other income

 

 

2,254

 

 

 

2,276

 

 

 

4,762

 

 

 

3,860

 

Loss before income taxes

 

 

(11,754

)

 

 

(6,063

)

 

 

(19,926

)

 

 

(15,154

)

Income tax expense

 

 

32

 

 

 

16

 

 

 

50

 

 

 

25

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(11,786

)

 

$

(6,079

)

 

$

(19,976

)

 

$

(15,179

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on short-term investments

 

 

(146

)

 

 

(64

)

 

 

(303

)

 

 

(109

)

Foreign currency translation gain (loss)

 

 

14

 

 

 

(1

)

 

 

20

 

 

 

(4

)

Total other comprehensive loss

 

 

(132

)

 

 

(65

)

 

 

(283

)

 

 

(113

)

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss

 

$

(11,918

)

 

$

(6,144

)

 

$

(20,259

)

 

$

(15,292

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic & diluted

 

$

(0.29

)

 

$

(0.16

)

 

$

(0.49

)

 

$

(0.40

)

Weighted-average shares used in computing net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to common stock, basic & diluted

 

 

40,743,786

 

 

 

38,455,955

 

 

 

40,627,363

 

 

 

37,649,521

 

 

 

 

 

 

 

img261313502_0.jpg

 

 

 

RxSIGHT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In thousands, except share and per share amounts)

 

 

 

 

June 30,

 

 

December 31,

 

 

 

2025

 

 

2024

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

40,355

 

 

$

16,706

 

Short-term investments

 

 

187,136

 

 

 

220,517

 

Accounts receivable, net

 

 

28,058

 

 

 

30,050

 

Inventories, net

 

 

25,061

 

 

 

22,009

 

Prepaid and other current assets

 

 

3,264

 

 

 

4,541

 

Total current assets

 

 

283,874

 

 

 

293,823

 

Property and equipment, net

 

 

13,255

 

 

 

12,413

 

Operating leases right-of-use assets

 

 

10,588

 

 

 

11,217

 

Restricted cash

 

 

750

 

 

 

750

 

Other assets

 

 

542

 

 

 

360

 

Total assets

 

$

309,009

 

 

$

318,563

 

Liabilities and stockholders' equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,348

 

 

$

4,544

 

Accrued expenses and other current liabilities

 

 

15,934

 

 

 

20,358

 

Lease liabilities

 

 

1,101

 

 

 

974

 

Total current liabilities

 

 

20,383

 

 

 

25,876

 

Long-term lease liabilities

 

 

10,614

 

 

 

11,322

 

Other long-term liabilities

 

 

—

 

 

 

127

 

Total liabilities

 

 

30,997

 

 

 

37,325

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Common stock, $0.001 par value, 900,000,000 shares authorized,
  40,913,380 shares issued and outstanding as of June 30, 2025 and
  40,428,220 shares issued and outstanding as of December 31, 2024

 

 

41

 

 

 

40

 

Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued
  and outstanding

 

 

—

 

 

 

—

 

Additional paid-in capital

 

 

920,159

 

 

 

903,127

 

Accumulated other comprehensive (loss) income

 

 

(117

)

 

 

166

 

Accumulated deficit

 

 

(642,071

)

 

 

(622,095

)

Total stockholders' equity

 

 

278,012

 

 

 

281,238

 

Total liabilities and stockholders' equity

 

$

309,009

 

 

$

318,563

 

 

 

 

img261313502_0.jpg

Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss) and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, when calculating adjusted net earnings (loss) and adjusted net earnings (loss) per share, basic and diluted, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share

Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

 

 

 

img261313502_0.jpg

 

 

Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:

 

RxSIGHT, INC.

GAAP To NON-GAAP RECONCILIATIONS (UNAUDITED)

(In thousands, except share and per share amounts)

 

 

 

Three months ended June 30,

 

 

For the six months ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss available to stockholders, basic and diluted

 

$

(11,786

)

 

$

(6,079

)

 

$

(19,976

)

 

$

(15,179

)

Add:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

8,547

 

 

 

6,105

 

 

 

15,687

 

 

 

10,801

 

Adjusted net earnings (loss) income available to common stockholders, basic and diluted:

 

$

(3,239

)

 

$

26

 

 

$

(4,289

)

 

$

(4,378

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding, basic

 

 

40,743,786

 

 

 

38,455,955

 

 

 

40,627,363

 

 

 

37,649,521

 

Weighted-average shares outstanding, diluted

 

 

40,743,786

 

 

 

44,799,864

 

 

 

40,627,363

 

 

 

37,649,521

 

Adjusted net earnings (loss) per share, basic

 

$

(0.08

)

 

$

0.00

 

 

$

(0.11

)

 

$

(0.12

)

Adjusted net earnings (loss) per share, diluted

 

$

(0.08

)

 

$

0.00

 

 

$

(0.11

)

 

$

(0.12

)